Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The patent portfolio for Richard G Pestell currently operates within the Biotechnology & Pharmaceuticals technology area. This portfolio shows a highly concentrated prosecution footprint, as evidenced by the presence of 1 distinct examiner and 1 distinct art unit. Such concentration suggests that the current legal strategy is focused on a specific niche or an active application within the broader pharmaceutical sector.
The primary point of contact for this portfolio is examiner DENT, ALANA HARRIS. This individual is identified as the busiest examiner for the portfolio, currently managing 1 busiest examiner pending office action. This specific action represents the entirety of the pending office actions for the portfolio, which currently stands at 1.
Practitioners managing this portfolio deal with a very narrow administrative scope. Because there is only 1 distinct examiner and 1 distinct art unit involved, the prosecution experience is centralized. This centralization means that the outcome of the 1 pending office action will significantly impact the immediate status of the Richard G Pestell holdings in the Biotechnology & Pharmaceuticals space. The focus on an individual examiner allows for a more tailored approach to the outstanding matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17785385 | METHODS, KITS AND COMPOSITIONS FOR REDUCING CARDIOTOXICITY ASSOCIATED WITH CANCER THERAPIES | DENT, ALANA HARRIS | 53d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17785385 | METHODS, KITS AND COMPOSITIONS FOR REDUCING CARDIOTOXICITY ASSOCIATED WITH CANCER THERAPIES | DENT, ALANA HARRIS | 53d overdue |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17785385 | METHODS, KITS AND COMPOSITIONS FOR REDUCING CARDIOTOXICITY ASSOCIATED WITH CANCER THERAPIES | DENT, ALANA HARRIS | 1643 | §102§103§112 | Final Rejection | 53d overdue | Pending | Jun 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRichard G Pestell has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alana Harris Dent has the most, with 1 of Richard G Pestell's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
